Seres' SER-109 gets breakthrough designation

FDA granted breakthrough therapy designation to microbiome therapy SER-109 from Seres Therapeutics Inc. (Cambridge, Mass.) to treat recurrent Clostridium difficile infections. Seres expects data from...